Description
Factor VIII:C Polyclonal Antibody – Affinity Purified – Biotinylated
Affinity’s Factor VIII:C Polyclonal Antibody – Affinity Purified – Biotinylated is the highest level of our biotin conjugated Factor VIII:C antibodies. During the Antigen Affinity Purification process the IgG has had any non-specific immunoglobulin fraction eliminated which enriches the specificity of the remaining immunoglobulin towards the target antigen. The result is a very high-purity product with a substantially higher titre than whole or purified IgG. Our Factor VIII:C Polyclonal Antibody – Affinity Purified – Biotinylated is provided in a solution of HEPES buffered saline containing 50% glycerol (v/v) and has been conjugated with Biotin as an enzyme reporter. This antibody is generally intended for use as labelled primary antibodies in applications such as immunoassay and immunoblotting.
Product Code: SAF8C-APBIO
Retail Product Size: 0.1mg vial
Host Animal: Sheep Anti-Human Factor VIII:C Polyclonal Antibody – Affinity Purified – Biotinylated
Species Cross Reactivity: View Chart
Product Datasheet: Factor VIII F8 Polyclonal Antibody - affinity purified Biotin conjugated anti-human sheep IgG
Description of Factor VIII
Factor VIII (formerly referred to as antihemophilic globulin and Factor VIII:C) is a large glycoprotein (320 kDa) that circulates in plasma at approximately 200 ng/ml. Synthesized in the liver, the majority of Factor VIII is cleaved during expression, resulting in a heterogeneous mixture of partially cleaved forms of FVIII ranging in size from 200-280 kDa. The FVIII is stabilized by association with von Willebrand Factor to form a FVIII-vWF complex required for the normal survival of FVIII in vivo (t1/2 of 8-12 hours).
F.VIII is a pro-cofactor that is activated through limited proteolysis by thrombin. In this process F.VIIIa dissociates from vWF to combine with activated Factor IX, calcium and a phospholipid surface where it is an essential cofactor in the assembly of the Factor X activator complex. Once dissociated from vWF, FVIIIa is susceptible to inactivation by activated Protein C and by non-enzymatic decay.
Hemophilia A is a congenital bleeding disorder resulting from an X-chromosome-linked deficiency of FVIII. The severity of the deficiency generally correlates with the severity of the disease. Some Hemophiliacs (~10%) produce a FVIII protein that is partially or totally inactive. The production of neutralizing antibodies to FVIII also occurs in 5-20% of Hemophiliacs 1-3.
References and Review
- Lollar P, Fay PJ, Fass DN; Factor VIII and Factor VIIIa. Methods in Enzymology, 222, pg 122, 1993.
- Hoyer, LW, Wyshock EG, Colman RW, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 109-133, J.B. Lippincott Co., Philadelphia, 1994.
- Pittman DD, Kaufman RJ. Structure-Function Relationships of Factor VIII Elucidated through Recombinant DNA Technology. Thromb. Haemostasis. 61:161-165, 1989.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
② 应取pH8.0，这样可使核苷酸带较多负电荷，利于吸附于阴离子交换树脂柱。虽然pH 11.4时核苷酸带有更多的负电荷，但pH过高对分离不利。
③ 当不考虑树脂的非极性吸附时，根据核苷酸负电荷的多少来决定洗脱速度，则洗脱顺序为CMP>AMP> GMP > UMP，但实际上核苷酸和聚苯乙烯阴离子交换树脂之间存在着非极性吸附，嘌呤碱基的非极性吸附是嘧啶碱基的3倍。静电吸附与非极性吸附共同作用的结果使洗脱顺序为：CMP> AMP > UMP >GMP。
但是最好还是不要用，影响实验就不好了。
TAE是使用最广泛的缓冲系统。其特点是超螺旋在其中电泳时更符合实际相对分子质量（TBE中电泳时测出的相对分子质量会大于实际分子质量），且双链线状DNA在其中的迁移率较其他两种缓冲液快约10%，电泳大于13kb的片段时用TAE缓冲液将取得更好的分离效果，此外，回收DNA片段时也易用TAE缓冲系统进行电泳。TAE的缺点是缓冲容量小，长时间电泳（如过夜）不可选用，除非有循环装置使两极的缓冲液得到交换。 50×TAE Buffer 配制方法： 1. 称量Tris 242g，Na2EDTA.2H2O 37.2g 于1L烧杯中； 2.向烧杯中加入约800ml去离子水，充分搅拌均匀； 3加入57.1ml的冰乙酸，充分溶解； 4.加去离子水定容至1L后，室温保存。向左转|向右转
2.配好的EDTA不灭菌行不?放4度冰箱等过完年回来直接拿去配TAE
3.TAE配好后不用灭菌吧
此外，我们常常用“电泳法”判断液体的性质，是胶体还是溶液。在高中化学中我们就用过这种方法判断给定的液体是否为胶体。向左转|向右转
